Avinger, Inc. announced that it has entered into a Securities Purchase Agreement with new investor, Zylox-Tonbridge Medical Technology Co., Ltd., pursuant to which the Purchaser agreed to purchase the shares of the Company?s common stock, par value $0.001 per share and shares of two new series of the Company?s preferred stock for the aggregate gross proceeds of $15,000,000 on March 4, 2024. The purchaser agreed to purchase in two tranches. Each share of Series F Preferred Stock has a stated value of $1,000 and is initially convertible into approximately 273 shares of Common Stock at a conversion price equal to the Purchase Price, subject to the terms of the Certificate of Designation of Preferences, Rights, and Limitations of the Series F Preferred Stock.
Zylox-Tonbridge Medical Technology Co., Ltd.
Equities
2190
CNE100004JD2
Medical Equipment, Supplies & Distribution
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
10.72 HKD | -0.74% |
|
+7.20% | -13.83% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-13.83% | 450M | |
+10.87% | 126B | |
-2.27% | 10.98B | |
-23.89% | 6.87B | |
+50.07% | 6.51B | |
-34.16% | 3.98B | |
+8.50% | 3.44B | |
-20.67% | 2.44B | |
-19.65% | 1.88B | |
-23.49% | 1.72B |
- Stock Market
- Equities
- 2190 Stock
- News Zylox-Tonbridge Medical Technology Co., Ltd.
- Avinger, Inc. announced that it expects to receive $15 million in funding from Zylox-Tonbridge Medical Technology Co., Ltd.